Welcome to our dedicated page for Supernus Pharma news (Ticker: SUPN), a resource for investors and traders seeking the latest updates and insights on Supernus Pharma stock.
Supernus Pharmaceuticals (SUPN) is a leading biopharmaceutical innovator focused on developing advanced treatments for central nervous system disorders. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's clinical developments, regulatory milestones, and strategic initiatives in neurology and psychiatry.
Access comprehensive coverage of SUPN's progress in treating epilepsy, ADHD, and movement disorders through reformulated therapeutics. Our curated news feed includes updates on FDA submissions, partnership announcements, clinical trial results, and market expansion efforts – all essential for understanding the company's position in CNS therapeutics.
Key areas of focus include non-stimulant ADHD treatments, extended-release neurology medications, and novel approaches to Parkinson's-related conditions. Stay informed about SUPN's pipeline advancements and commercial strategies through verified press releases and objective analysis.
Bookmark this page for direct access to Supernus Pharmaceuticals' latest developments in neuroscience innovation. Check regularly for updates on product approvals, research collaborations, and financial performance indicators relevant to CNS treatment advancements.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced the upcoming filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2021. The company reaffirms its full-year 2022 financial guidance with anticipated total revenues between $640 million and $680 million, combined R&D and SG&A expenses of $460 million to $490 million, and operating earnings projected to be $20 million to $40 million. Additionally, a non-GAAP operating earnings estimate ranges from $130 million to $165 million.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced a delayed filing of its Annual Report on Form 10-K for the fiscal year ending December 31, 2021, via Form 12b-25 on March 1, 2022. This delay puts the company out of compliance with Nasdaq Rule 5250(c)(1). However, Supernus expects to file the report by April 4, 2022, to regain compliance. The company specializes in developing treatments for central nervous system diseases, including epilepsy and ADHD, and is working on new treatments for various CNS disorders.
Supernus Pharmaceuticals (Nasdaq: SUPN) announced that President and CEO Jack Khattar will participate in a fireside chat at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 1:30 p.m. ET. The discussion will focus on the company's activities in developing products for central nervous system diseases.
Investors can access a live webcast of the presentation on the company's website, with an archived replay available for 60 days post-conference.
Supernus Pharmaceuticals (SUPN) announced preliminary 2021 revenues of $579.8 million, an 11% increase from 2020, driven by product sales growth and the acquisition of Adamas Pharmaceuticals. The company reported net product sales of $567.5 million, with Qelbree prescriptions reaching 34,328 in Q4 2021, marking a 122% increase from Q3 2021. SPN-830's NDA has been accepted with a PDUFA date set for October 2022. However, operating earnings are expected to decline significantly, and cash reserves decreased to approximately $458.8 million, down from $772.9 million in 2020.
Supernus Pharmaceuticals (Nasdaq: SUPN) will announce its preliminary financial results for Q4 and full year 2021, along with its guidance for 2022, on February 28, 2022, after market close. A conference call hosted by CEO Jack Khattar and CFO Tim Dec will take place at 4:30 PM ET the same day. Investors can access the live webcast on the company's website. Supernus develops treatments for CNS diseases, with a portfolio covering epilepsy, migraine, and more.
Supernus Pharmaceuticals (Nasdaq: SUPN) has received notice from the FDA regarding its New Drug Application (NDA) resubmission for the apomorphine infusion device (SPN-830) aimed at treating motor fluctuations in Parkinson’s disease. The FDA has classified the review as Standard, with a timeline set for 10 months, leading to a target action date in early October 2022. Supernus plans to prepare for a commercial launch of SPN-830 in Q1 2023, contingent on FDA approval.
Supernus Pharmaceuticals (NASDAQ: SUPN) has resubmitted its New Drug Application (NDA) for the apomorphine infusion device (SPN-830) to treat motor fluctuations in Parkinson’s Disease (PD). This follows a Refusal to File (RTF) letter from the FDA in November 2020, which noted the application was incomplete. The resubmission is significant as SPN-830 could provide a novel treatment option for PD patients, offering a less invasive alternative for managing OFF episodes. The company remains focused on CNS disease treatments, with various approved and developing products in their pipeline.
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) announced it was targeted by a ransomware attack that began around mid-November 2021. The Company reported that the attack had no significant impact on its operations and that no ransom payments were made. Following detection, it engaged cybersecurity experts and successfully recovered the affected files. The Company remains vigilant, monitoring the situation and ensuring the protection of any confidential information. Despite the incident, Supernus continues to operate normally as it develops treatments for CNS diseases.
Supernus Pharmaceuticals has completed its acquisition of Adamas Pharmaceuticals, enhancing its Parkinson’s disease portfolio with GOCOVRI® and Osmolex ER®. The deal diversifies revenue streams, expected to yield synergies of $60M to $80M in the first year, and is projected to be accretive in 2022. Supernus offered $8.10 cash per share of Adamas, totaling about 77.3% tendered shares. Adamas stock will be delisted post-merger. The acquisition aligns with Supernus's strategy to strengthen its CNS product offerings, contributing to cash flow stability.
Supernus Pharmaceuticals (NASDAQ: SUPN) announced that the waiting period under the Hart-Scott-Rodino Act for its proposed acquisition of Adamas Pharmaceuticals (NASDAQ: ADMS) expired on November 22, 2021. The acquisition offer includes $8.10 per share in cash and two contingent value rights (CVRs) worth up to $1.00, dependent on achieving sales milestones by December 2024 and December 2025. The tender offer expires at 11:59 p.m. on November 23, 2021, unless extended. Upon completion, Adamas will become a wholly-owned subsidiary of Supernus.
FAQ
What is the current stock price of Supernus Pharma (SUPN)?
What is the market cap of Supernus Pharma (SUPN)?
